# Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation

> **NCT03792620** · PHASE3 · UNKNOWN · sponsor: **Grupo de Estudos Multicentricos em Onco-Hematologia** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma Stage I

## Interventions

- **COMBINATION_PRODUCT:** Cyclo Thal Dex Daratumumab

## Key facts

- **NCT ID:** NCT03792620
- **Lead sponsor:** Grupo de Estudos Multicentricos em Onco-Hematologia
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-20
- **Primary completion:** 2020-05
- **Final completion:** 2022-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792620, "Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03792620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*